Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →The peptides most studied for muscle growth and fat loss include growth-hormone secretagogues such as CJC-1295 with ipamorelin, GHRH analogs such as sermorelin and tesamorelin, and GLP-1 medicines such as semaglutide and tirzepatide for fat loss. Recovery peptides like BPC-157 and TB-500 have far less human evidence and should be viewed cautiously.
What are peptides, and how do they affect muscle and fat?
Peptides are short chains of amino acids. Some peptides act like signals in the body, including signals tied to appetite, growth hormone, inflammation, blood sugar, or tissue repair. The effect depends on the exact peptide, the dose studied, the person using it, and whether it has been tested in humans.
Muscle growth is not controlled by one switch. It depends on resistance training, enough protein, sleep, sex hormones, recovery, and total health. One key pathway is mTOR / muscle protein synthesis, which helps muscle rebuild after training, but pathway activity in a lab does not prove visible muscle gain in people 7.
The growth hormone and IGF-1 pathway can change body composition, fluid balance, glucose, and tissue growth. Medicines that raise GH or IGF-1 can also cause swelling, joint pain, numbness or tingling, headache, and glucose changes, and they need careful review in people with active cancer, pituitary disease, or diabetes risk 5, 8.
Can the same peptide build muscle and burn fat?
One peptide can affect more than one pathway, but that does not mean it reliably builds muscle and burns fat in the same person. The best evidence usually separates into three groups: GH-axis drugs, appetite-and-metabolic medicines, and recovery peptides.
Tesamorelin, brand name Egrifta, is a GHRH analog. In randomized trials in adults with HIV-associated abdominal fat, tesamorelin reduced visceral adipose tissue, but this evidence is for a specific medical population; individual results vary 9. Side effects in the label include injection-site reactions, fluid retention, muscle aches, glucose intolerance, and contraindications in pregnancy, active malignancy, and pituitary disruption 5.
GLP-1 and GIP/GLP-1 medicines work differently. Semaglutide and tirzepatide reduce appetite and improve glucose regulation; they are not designed to directly increase muscle size 1, 2. In weight-loss care, some lean mass can be lost along with fat mass, so clinicians often discuss resistance training and protein intake as part of a complete plan 10.
Which peptides are best studied for muscle growth?
Growth-hormone secretagogues and IGF-1-related compounds are the peptides most often discussed for muscle growth. The honest answer is that the human evidence for visible muscle gain in healthy adults is limited, and risks rise when hormones are pushed without medical oversight.
CJC-1295 + ipamorelin
CJC-1295 is a growth hormone-releasing hormone analog, and ipamorelin is a growth hormone secretagogue. Together, they are commonly discussed as a GH-axis pair: CJC-1295 signals the pituitary through the GHRH receptor, while ipamorelin acts through the ghrelin receptor family to pulse growth hormone release.
In a small human study, CJC-1295 increased growth hormone and IGF-1 for several days after single injections, with studied doses ranging from 30 to 250 μg/kg; that sentence describes the study design, not dosing advice 8. The study measured hormone changes, not proven muscle gain, fat loss, or athletic performance.
Realistic expectations should be modest. If a GH-axis peptide helps a person feel better recovered, that still does not prove new lean tissue. Risks include swelling, tingling, joint discomfort, headache, glucose changes, and unknown long-term effects, especially when obtained from research-chemical vendors rather than licensed clinical channels 8.
Sermorelin
Sermorelin is a GHRH analog, meaning it signals the pituitary gland to release growth hormone. It is often discussed in longevity care because it works upstream of GH release rather than replacing growth hormone directly.
Human endocrine studies show that sermorelin can stimulate GH release, but it is not a proven muscle-building drug for healthy adults 11. At Chia, sermorelin is available for eligible patients as injection, nasal spray, and tablets after licensed-provider review; plans for sermorelin injection currently start at $199/mo.
The main risks are hormone-pathway effects. Possible side effects include injection-site reactions, flushing, headache, dizziness, swelling, glucose changes, and concern in people with pituitary tumors, active cancer, uncontrolled diabetes, or pregnancy-related issues 11.
Tesamorelin
Tesamorelin, brand name Egrifta, is a GHRH analog approved for a narrow use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The FDA-approved label describes 2 mg injected once daily for that approved use; this is a label fact, not personal dosing advice 5.
Tesamorelin can raise IGF-1 and reduce visceral adipose tissue in the studied HIV-lipodystrophy population 9. It should not be framed as a general bodybuilding peptide. Side effects and contraindications matter: injection reactions, edema, muscle aches, glucose intolerance, pregnancy, active malignancy, and pituitary-axis disruption are key label concerns 5.
IGF-1 LR3
IGF-1 LR3 is a modified insulin-like growth factor-1 analog discussed in bodybuilding circles. It is meant to mimic or extend IGF-1 signaling, a growth pathway involved in cell growth, glucose handling, and muscle protein turnover.
High-quality human trials showing that IGF-1 LR3 safely increases muscle size in healthy adults are lacking. That gap matters because IGF-1 biology is not a simple “more is better” system; excess signaling may affect glucose and tissue growth pathways 12.
Potential concerns include low blood sugar, swelling, soft-tissue growth, headaches, and theoretical cancer-related risk because IGF-1 signaling is involved in cell proliferation 12. For competitive athletes, growth factors and related agents may also create anti-doping risk 6.
Which peptides are best studied for fat loss?
For fat loss, the strongest evidence is not from bodybuilding peptides. Semaglutide and tirzepatide have large randomized trials for weight management in eligible patients, while tesamorelin has evidence for visceral fat in HIV-associated lipodystrophy 3, 4, 5, 9.
Semaglutide (Ozempic, Wegovy) and compounded semaglutide via 503A pharmacy
Semaglutide, sold under brand names including Ozempic and Wegovy, is a GLP-1 receptor agonist; compounded semaglutide may be dispensed by licensed 503A pharmacies when legally permitted and prescribed for an individual patient. Wegovy is FDA-approved for chronic weight management in specific adults and adolescents, while Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction in certain adults 1, 13.
The FDA-approved Wegovy label describes a starting dose of 0.25 mg once weekly for the first 4 weeks, with stepwise titration to a 2.4 mg once-weekly maintenance dose; these are label facts, not instructions for any reader 1. In the STEP 1 trial, semaglutide 2.4 mg once weekly produced greater average weight loss than placebo in adults with overweight or obesity; individual results vary, and results are not established for compounded formulations 3.
Semaglutide’s main trade-off is tolerability and screening. Common risks include nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder disease, pancreatitis warnings, kidney injury risk with severe dehydration, and a boxed warning about thyroid C-cell tumors 1.
Tirzepatide (Mounjaro, Zepbound) and compounded tirzepatide via 503A pharmacy
Tirzepatide, sold as Mounjaro and Zepbound, is a GIP/GLP-1 receptor agonist; compounded tirzepatide may be dispensed by licensed 503A pharmacies when legally permitted and prescribed for an individual patient. Zepbound is FDA-approved for chronic weight management in certain adults, and Mounjaro is FDA-approved for type 2 diabetes 2, 14.
The FDA-approved Zepbound label describes once-weekly injections with maintenance doses of 5 mg, 10 mg, or 15 mg after dose escalation; these are label facts, not personal dosing advice 2. In SURMOUNT-1, tirzepatide produced greater average weight loss than placebo in adults with obesity or overweight; individual results vary, and results are not established for compounded formulations 4.
Tirzepatide risks overlap with GLP-1 medicines. They include nausea, vomiting, diarrhea, constipation, pancreatitis warnings, gallbladder disease, possible hypoglycemia when used with insulin or insulin secretagogues, kidney injury risk with severe dehydration, and a boxed warning about thyroid C-cell tumors 2.
3-min quiz
Considering a GLP-1 option?
Chia offers compounded semaglutide injections with plans currently starting at $249/mo and compounded tirzepatide tablets or injections, with tablet plans currently starting at $249/mo and injection plans currently starting at $299/mo. A prescription requires an online medical evaluation by a licensed provider and is not guaranteed. Compounded drugs are not FDA-approved.
Tesamorelin (Egrifta) for visceral fat
Tesamorelin is best understood as a targeted visceral-fat medicine for one defined population: adults with HIV-associated lipodystrophy and excess abdominal fat 5. It is not a general weight-loss drug, and it is not a substitute for nutrition, training, or obesity medicine.
In clinical trials, tesamorelin reduced visceral adipose tissue in adults with HIV-associated abdominal fat, with individual variation 9. Risks include injection reactions, edema, muscle aches, glucose intolerance, increased IGF-1, pregnancy contraindication, and active-malignancy concerns 5.
AOD-9604
AOD-9604 is a fragment of human growth hormone studied for obesity-related biology. It was designed to explore fat-metabolism effects without the full growth-promoting effects of growth hormone.
Human obesity research has not established AOD-9604 as an approved fat-loss medicine. In a randomized trial of oral AOD9604 in adults with obesity, the study did not show a clinically meaningful weight-loss drug profile that led to FDA approval 15.
The main issue is uncertainty. Long-term safety, purity, and real-world adverse effects are not as well characterized as they are for approved obesity medicines, and athletes should treat it as a sport-rule risk until verified with their governing body 6, 15.
What peptides help with recovery?
BPC-157 and TB-500 are often discussed for tendons, ligaments, muscle strains, and recovery. The honest answer is that most supportive evidence is animal, mechanistic, or early-stage, not large human trials showing reliable recovery outcomes.
BPC-157
BPC-157 is a synthetic peptide related to a gastric protein fragment. In animal models, it has been investigated for tendon, ligament, nerve, muscle, and gastrointestinal injury biology, including effects on blood-vessel signaling and tissue repair 16.
Animal data can help explain why people are interested, but it does not prove that BPC-157 heals sports injuries in humans. Chia does not offer BPC-157. Key concerns include uncertain human dosing, unknown long-term safety, contamination risk from non-prescription vendors, and anti-doping issues 6, 16.
TB-500 (thymosin beta-4 fragment)
TB-500 usually refers to a thymosin beta-4 fragment. Thymosin beta-4 is involved in actin binding, cell movement, angiogenesis, and wound-healing biology, which is why it appears in recovery discussions 17.
The problem is translation. Tissue-repair biology does not equal proven injury recovery in athletes. Chia does not offer TB-500. Risks include limited human safety data for athletic recovery, uncertain purity outside licensed pharmacy channels, possible immune or tissue-growth concerns, and sport-rule risk 6, 17.
How do popular peptide stacks compare?
Peptide stacks are combinations commonly discussed in research, sports-medicine settings, or compounding-pharmacy practice. A stack is not automatically better than one medicine; combining agents can increase side effects and make it harder to know what caused a problem.
| Option or stack | Why people ask about it | Human evidence level | Realistic expectation | Key safety caveat |
|---|---|---|---|---|
| CJC-1295 + ipamorelin | GH-axis signaling, recovery, body composition | Small human hormone data for CJC-1295; limited combination outcome trials | May change GH/IGF-1 markers, but proven muscle gain is not established | Fluid retention, glucose changes, numbness, joint pain, unknown long-term effects 8 |
| Sermorelin + GLP-1 | Weight care plus GH-axis support in clinician-guided settings | Combination-specific outcome trials are limited | May fit select clinical goals, but it is not a universal lean-muscle protocol | Hormone-pathway risks plus GLP-1 GI, gallbladder, pancreatitis, and thyroid-warning concerns 1, 2, 11 |
| Tesamorelin alone | Visceral abdominal fat in HIV-associated lipodystrophy | Randomized human trials in the approved population | Best evidence is for visceral fat in that specific condition | Glucose intolerance, edema, injection reactions, malignancy and pregnancy contraindications 5, 9 |
| Semaglutide or tirzepatide | Clinically studied weight management | Large randomized weight-management trials for the active ingredients | Fat-loss support for eligible patients; not a direct muscle-growth drug | GI effects, gallbladder risk, pancreatitis warnings, thyroid tumor boxed warning 1, 2, 3, 4 |
| BPC-157 + TB-500 | Soft-tissue recovery interest | Mostly animal, mechanistic, or early tissue-repair literature | Promising biology, but human recovery outcomes are not established | Limited human safety data, anti-doping risk, and purity concerns 6, 16, 17 |
| AOD-9604 | Fat-loss interest without full GH effects | Limited human obesity data | Not established as an approved obesity medicine | Unknown long-term safety and product-quality concerns 15 |
A useful filter is simple: Was the outcome studied in humans like me? Were side effects tracked in large trials? Was the product prescribed and dispensed through licensed channels? For fat loss, GLP-1-based medicines have clearer human evidence than most wellness peptides, but they still require careful screening 1, 2, 3, 4.
Are peptides safer than anabolic steroids?
Peptides are not anabolic-androgenic steroids, but that does not make them automatically safe. Safety depends on the compound, health history, source, dose studied, drug interactions, and whether a licensed clinician is supervising care.
Anabolic-androgenic steroids can carry serious risks, including testosterone suppression, infertility, liver injury, acne, mood changes, blood pressure changes, and cardiovascular concerns 18. Peptides may avoid some steroid-specific risks, but GH/IGF-1 agents can still cause swelling, nerve symptoms, glucose changes, and cancer-related cautions 5, 8, 12.
For competitive athletes, “not a steroid” does not mean “allowed.” WADA prohibits many growth-hormone secretagogues, growth factors, and related substances, which may include several peptides discussed in bodybuilding contexts 6.
What are the risks and side effects?
The main risks fall into four groups: drug side effects, hormone-pathway effects, product-quality problems, and legal or sport-rule issues. Research-use-only peptides are especially risky because they may not be made, tested, or dispensed like prescription medications.
- GH-axis peptides: swelling, joint pain, carpal-tunnel-like symptoms, headache, glucose changes, and concern in people with active cancer, pituitary disease, or diabetes risk 5, 8, 11.
- GLP-1 and GIP/GLP-1 medicines: nausea, vomiting, diarrhea, constipation, gallbladder disease, pancreatitis warnings, kidney injury risk with severe dehydration, and thyroid C-cell tumor boxed warning 1, 2.
- Tesamorelin: injection reactions, fluid retention, muscle aches, glucose intolerance, increased IGF-1, and contraindications such as pregnancy and active malignancy 5.
- BPC-157, TB-500, IGF-1 LR3, and AOD-9604: limited human safety data for muscle growth, fat loss, or recovery; product purity and contamination are major concerns 12, 15, 16, 17.
- Athletic eligibility: some peptides and related pathways are prohibited by WADA and may disqualify competitive athletes 6.
A clinician may ask about thyroid cancer history, MEN2, pancreatitis, gallbladder disease, diabetes medications, pregnancy plans, cancer history, pituitary disease, kidney disease, and athletic testing rules before discussing options 1, 2, 5, 6.
Are these peptides legal and FDA-approved?
FDA status is mixed. Semaglutide, tirzepatide, and tesamorelin have FDA-approved uses, while most bodybuilding and recovery peptides discussed online do not have FDA approval for muscle growth, fat loss, or recovery 1, 2, 5.
| Compound | FDA-approved use relevant here | Common non-approved discussion | Access and safety note |
|---|---|---|---|
| Semaglutide | Wegovy: chronic weight management in eligible patients; Ozempic: type 2 diabetes and certain cardiovascular-risk uses | Muscle growth | Prescription evaluation and appropriate pharmacy dispensing are required 1, 13 |
| Tirzepatide | Zepbound: chronic weight management in eligible adults; Mounjaro: type 2 diabetes | Muscle growth | Prescription evaluation and appropriate pharmacy dispensing are required 2, 14 |
| Tesamorelin | Excess abdominal fat in adults with HIV-associated lipodystrophy | General weight loss, athletic cutting, bodybuilding | Label contraindications include pregnancy, active malignancy, and pituitary disruption 5 |
| Sermorelin | No current FDA-approved muscle-growth or fat-loss indication | Muscle growth, anti-aging, fat loss | At Chia, it is available only after licensed-provider evaluation |
| CJC-1295, ipamorelin, BPC-157, TB-500, IGF-1 LR3, AOD-9604 | No FDA-approved muscle-growth, recovery, or fat-loss use | Bodybuilding, injury recovery, cosmetic fat loss | Often sold as research-use-only chemicals outside licensed clinical channels 15, 16, 17 |
Some longevity peptides are currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23-24, 2026. This review process does not mean a peptide is FDA-approved, and it does not guarantee future compounding status 19.
How do you get peptides or GLP-1s from a licensed provider?
The safest legal path starts with a medical evaluation. A prescription is not guaranteed; a licensed clinician must decide whether a medication fits your history, and a licensed pharmacy must dispense it when allowed by federal and state rules 20.
At Chia, treatment is 100% online. You complete a short health questionnaire, then one of our licensed US providers reviews your history and prescribes only when clinically appropriate. Medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door.
For weight care, Chia offers compounded semaglutide injections and compounded tirzepatide tablets or injections, including provider-guided microdosing plans where appropriate. For longevity care, Chia offers sermorelin, NAD+, and glutathione, plus protocols such as GLP-1 + Sermorelin, Weight + Energy, and Foundation Longevity.
| Chia option | Forms listed in Chia catalog | Current starting price | How dosing works |
|---|---|---|---|
| Semaglutide | Injection | Plans currently start at $249/mo | Provider-guided dosing; microdosing plans available when appropriate |
| Tirzepatide | Tablets and injection | Tablets from $249/mo; injection from $299/mo | Provider-guided dosing; microdosing plans available when appropriate |
| Sermorelin | Injection, nasal spray, tablets | Injection plans currently start at $199/mo | Provider-guided dosing and follow-up through the patient portal |
| NAD+ | Injection and nasal spray | Injection from $199/mo; nasal spray from $129/mo | Provider-guided use as part of eligible longevity or energy-focused care |
| Glutathione | Injection and nasal spray | Injection plans currently start at $199/mo | Provider-guided use as part of eligible longevity care |
We do not present research-only peptides like BPC-157, TB-500, IGF-1 LR3, AOD-9604, CJC-1295, or ipamorelin as Chia products. For those topics, our role is education: helping you understand the evidence, risks, regulatory status, and whether a licensed option better fits your goals.
Frequently asked questions
The most discussed are CJC-1295 with ipamorelin, sermorelin, and IGF-1-related compounds. Human evidence for visible muscle gain in healthy adults is limited. GH/IGF-1 pathway risks include swelling, numbness, joint pain, glucose changes, and cancer-related cautions.
Some peptides affect pathways tied to body composition, but no non-approved peptide stack is FDA-approved to build muscle and reduce fat in healthy adults. GLP-1 medications have stronger fat-loss evidence for eligible patients; compounded GLP-1 drugs are not FDA-approved and do not have FDA-evaluated outcomes data.
CJC-1295 acts like a growth hormone-releasing hormone analog, while ipamorelin is a growth hormone secretagogue. Together, they are intended to signal more growth hormone release, but combination-specific human outcome trials for muscle growth and fat loss are limited.
Tesamorelin is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss. In its approved population, trials showed visceral-fat reduction, but risks include injection reactions, fluid retention, glucose intolerance, pregnancy contraindication, and active-malignancy concerns.
BPC-157 and TB-500 are studied or discussed for tissue repair and recovery, but they are not FDA-approved for injury recovery, muscle growth, or fat loss. Most evidence is animal, mechanistic, or early-stage, and product quality can be a major concern outside licensed channels.
Not automatically. Peptides differ from anabolic steroids, but GH-axis and IGF-1-related peptides can still cause side effects, interact with health conditions, and violate sport rules. Safety depends on the exact compound, source, health history, and clinician oversight.
Many growth-hormone secretagogues, growth factors, and related substances are prohibited by WADA. Athletes should check the current prohibited list and their sport’s rules before using any peptide, even if it is not an anabolic steroid.
AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed clinician still decides whether any medication or compounded option is appropriate; the AI agent does not prescribe.
3-min quiz
Start with a licensed evaluation
If you are comparing GLP-1 medications, compounded options, or Chia’s offered longevity treatments, our licensed providers can review your health history and goals online. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
References
- 1.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. 2024.
- 2.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. 2024.
- 3.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- 4.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- 5.U.S. Food and Drug Administration. Egrifta SV (tesamorelin) prescribing information. 2023.
- 6.World Anti-Doping Agency. The 2026 Prohibited List: International Standard. 2026.
- 7.Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nature Cell Biology. 2001.
- 8.Ionescu M, Frohman LA. Pulsatile secretion of growth hormone and insulin-like growth factor-I following administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006.
- 9.Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007.
- 10.Heymsfield SB, Coleman LA, Miller R, et al. Effect of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Journal of the Endocrine Society. 2021.
- 11.Thorner MO, Reschke J, Chitwood J, et al. Sermorelin: a review of clinical use of growth hormone-releasing hormone analog therapy. Clinical Therapeutics. 1996.
- 12.Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer. 2008.
- 13.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. 2025.
- 14.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information. 2024.
- 15.Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on body weight and metabolic parameters in obese subjects. International Journal of Obesity. 2001.
- 16.Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract, ligament, tendon, muscle, and nerve injury. Current Pharmaceutical Design. 2018.
- 17.Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005.
- 18.Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews. 2014.
- 19.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting materials and 503A Bulks List discussion calendar. 2026.
- 20.U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. 2024.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
